The Phase II BEAVER trial reported clinical activity for the MEK inhibitor binimetinib combined with the BRAF inhibitor encorafenib in advanced solid tumors harboring non‑V600E BRAF alterations. Investigators led by Rose, Maxwell and Rousselle presented objective responses and disease control in a subset of patients whose tumors lack the canonical V600E mutation. The study highlights a precision‑medicine approach that targets diverse BRAF variants outside the common hotspot. Authors provided response rates and safety profiles to inform next steps for trial design and patient selection. The results suggest an expanded biomarker strategy beyond V600E for BRAF‑targeted regimens.